Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
|Approved Prescription Products|
|Approved Generic Prescription Products||Not Available|
|Approved Over the Counter Products||Not Available|
|Unapproved/Other Products||Not Available|
|International Brands||Not Available|
|Brand mixtures||Not Available|
|Weight||Average: 390.354 |
Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)
|Structured Indications||Not Available|
Regadenoson rapidly increases coronary blood flow (CBF) which is sustained for a short duration. Mean average peak velocity increased to greater than twice baseline by 30 seconds and decreased to less than twice the baseline level within 10 minutes. Myocardial uptake of the radiopharmaceutical is proportional to (CBF). Regadenoson increases blood flow in normal coronary arteries but not in stenotic (blocked) arteries. The significance of this finding is that stenotic arteries will take up less of the radiopharmaceutical than normal coronary arteries, resulting in a signal that is less intense in these areas.
|Mechanism of action|
Regadenoson is an selective low-affinity (Ki= 1.3 µM) A2A receptor agonist that mimics the effects of adenosine in causing coronary vasodilatation and increasing myocardial blood flow. It is a very weak agonist of the A1 adenosine receptor (Ki > 16.5 µM). Furthermore, it has negligible affinity to A2B and A3 adenosine receptors. Regadenoson is undergoing trials for use in pharmacological stress tests. Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.
The pharmacokinetic profile of regadenoson is best described by a 3-compartment model.
T max, injection = 1 to 3 minutes;
Onset of pharmacodynamic response = 1 to 3 minutes;
|Volume of distribution|
Central compartment: 11.5 L; Steady state: 78.7 L
|Protein binding||Not Available|
The metabolism of regadenoson is unknown in humans. The cytochrome P450 enzyme system is not likely to be involved with the metabolism of regadenoson.
|Route of elimination|
58% of total regadenoson eliminate is via renal excretion
Initial phase: 2-4 minutes; Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); Terminal phase: 2 hours
Average plasma renal clearance = 450 mL/min. As this value is larger than the glomerular filtration rate, this suggests occurrence of renal tubular secretion.
The most common (incidence ≥ 5%) adverse reactions to regadenoson are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. MTD (male, supine position): 20 µg/kg; MTD (male, standing position): 10 µg/kg;
|Pharmacogenomic Effects/ADRs||Not Available|
|Food Interactions||Not Available|
|Synthesis Reference||Not Available|
|ATC Codes||C01EB21 — Regadenoson|
|AHFS Codes||Not Available|
|PDB Entries||Not Available|
|FDA label||Download (176 KB)|
|MSDS||Download (479 KB)|
|Experimental Properties||Not Available|
|Predicted ADMET features|
|Mass Spec (NIST)||Not Available|
|Description||This compound belongs to the class of chemical entities known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.|
|Super Class||Organic compounds|
|Class||Nucleosides, nucleotides, and analogues|
|Sub Class||Purine nucleosides|
|Direct Parent||Purine nucleosides|
|Alternative Parents||Glycosylamines / 6-aminopurines / Pentoses / Pyrazole-4-carboxamides / Aminopyrimidines and derivatives / Primary aromatic amines / Imidolactams / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Oxolanes / Secondary carboxylic acid amides / Amino acids and derivatives / Secondary alcohols / Azacyclic compounds / Oxacyclic compounds / Primary alcohols / Hydrocarbon derivatives / Organic oxides / Organopnictogen compounds|
|Substituents||Purine nucleoside / Glycosyl compound / N-glycosyl compound / 6-aminopurine / Pentose monosaccharide / Imidazopyrimidine / Purine / Pyrazole-4-carboxamide / Aminopyrimidine / N-substituted imidazole/ Monosaccharide / Primary aromatic amine / Pyrimidine / Imidolactam / Oxolane / Pyrazole / Heteroaromatic compound / Azole / Vinylogous amide / Imidazole / Carboxamide group / Amino acid or derivatives / Secondary alcohol / Secondary carboxylic acid amide / Carboxylic acid derivative / Oxacycle / Azacycle / Organoheterocyclic compound / Organic oxygen compound / Amine / Alcohol / Organic nitrogen compound / Hydrocarbon derivative / Organic oxide / Organopnictogen compound / Primary amine / Primary alcohol / Organooxygen compound / Organonitrogen compound / Aromatic heteropolycyclic compound|
|Molecular Framework||Aromatic heteropolycyclic compounds|
|External Descriptors||Not Available|
- Pharmacological action
- General Function:
- Identical protein binding
- Specific Function:
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
- Gene Name:
- Uniprot ID:
- Uniprot Name:
- Adenosine receptor A2a
- Molecular Weight:
- 44706.925 Da
- Zoghbi GJ, Iskandrian AE: Selective adenosine agonists and myocardial perfusion imaging. J Nucl Cardiol. 2012 Feb;19(1):126-41. doi: 10.1007/s12350-011-9474-9. [PubMed:22130964 ]